Search reports, ask a question, or jump to a page.
The problem
Intervention: Nirsevimab, a long-acting monoclonal antibody administered as a preventive treatment
Who it was tested with: Children under 24 months of age who underwent nucleic acid testing for RSV; compared groups who received nirsevimab at different time intervals (within 6 months, 6-11 months, beyond 12 months) versus those who received no nirsevimab.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"The participants were children under 24 months of age who required nucleic acid testing for RSV between July 2023 and June 2025" and "Children who received the last dose of nirsevimab within 6 months, between 6 and 11 months, and beyond 12 months were compared with those who did not receive any nirsevimab dose...after propensity score matching." This represents a quasi-experimental design using propensity score matching to create comparable groups from observational data.
Retrospective observational study using database records without randomization; potential unmeasured confounding; authors explicitly state results require cautious interpretation due to important limitations not detailed in the abstract; cannot establish causation definitively.
Across countries and designs
1 study · 0 countries
